Buy Now
Multiple Myeloma Market Size, Share, Growth & Industry Analysis, By Drug Class (Immunomodulatory Drugs, Proteasome Inhibitors, Others), By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Other Therapies), By Disease Type, By Route of Administration, By Distribution Channel, and Regional Analysis, 2024-2031
Pages: 250 | Base Year: 2023 | Release: May 2025 | Author: Versha V.
The market refers to the global economic landscape encompassing the research, development, approval, commercialization, distribution, and sales of therapies aimed at treating multiple myeloma, a type of blood cancer. This market includes pharmaceutical companies, biotech firms, healthcare providers, regulatory bodies, and payers.
It spans drug therapies, diagnostics, clinical trials, pricing strategies, reimbursement models, and market access initiatives. The report offers a thorough assessment of the main factors driving the market, along with detailed regional analysis and the competitive landscape influencing market dynamics.
The global multiple myeloma market size was valued at USD 23.20 billion in 2023 and is projected to grow from USD 25.17 billion in 2024 to USD 44.82 billion by 2031, exhibiting a CAGR of 8.59% during the forecast period.
The market is registering steady growth driven by rising global incidence rates, increasing geriatric population, and advances in diagnostic technologies. Significant R&D investments and the introduction of innovative therapies, such as immunomodulators, monoclonal antibodies, and CAR-T cell therapies, are enhancing treatment efficacy and survival outcomes.
Major companies operating in the multiple myeloma industry are Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, GSK plc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi, AbbVie Inc., Legend Biotech, Arcellx, HaemaLogiX Ltd., Karyopharm, Oncopeptides AB, F. Hoffmann-La Roche Ltd, and Takeda Pharmaceutical Company Limited.
Additionally, the integration of advanced technologies such as genomics and precision medicine is enabling more personalized treatment approaches, driving better patient outcomes. The expanding pipeline of novel therapeutics and supportive care drugs is contributing to the market dynamism.
Market Driver
Expanding Treatment Options for Ineligible Multiple Myeloma Patients
The increasing availability of innovative therapies for patients with multiple myeloma who are not eligible for stem cell transplantation is driving the market. These patients, often older or with other health conditions that prevent them from undergoing the procedure, require alternative treatment options that can manage the disease effectively.
The development of targeted therapies, including combination treatments, is enhancing survival rates for these patients and helping to expand the market. Improving treatment access and outcomes for this specific patient group aids in the overall market growth, as more treatment options become available to those who would otherwise have limited choices.
Market Challenge
Limited Treatment Options for Relapsed or Refractory Multiple Myeloma
A major challenge in the multiple myeloma market is the limited treatment options for patients with relapsed or refractory multiple myeloma. Despite advancements in therapy, multiple myeloma remains an incurable disease, and most patients will eventually experience a relapse.
When the disease becomes refractory to initial treatments, it becomes harder to manage, as it often becomes less responsive to standard therapies. This makes it increasingly difficult to offer effective treatment alternatives, which can negatively affect patient outcomes. The development of novel therapies targeting resistant forms of multiple myeloma addresses this challenge.
Additionally, clinical trials and ongoing research are crucial in identifying and evaluating new treatment approaches to expand the therapeutic options available for patients with advanced multiple myeloma.
Market Trend
Growing Adoption of Monoclonal Antibodies in Multiple Myeloma Treatment
The growing adoption of monoclonal antibodies in multiple myeloma treatment is reshaping the therapeutic landscape. Monoclonal antibodies are engineered to target specific proteins on myeloma cells, helping the immune system fight the disease more efficiently.
Supported by clinical trial successes and regulatory approvals, these therapies offer improved outcomes compared to traditional treatments. They offer a more precise and less toxic approach compared to traditional treatments, improving patient outcomes, reducing disease progression, and enhancing survival rates.
The market continues to expand as these therapies become more integrated into standard treatment protocols, providing more treatment options for patients at various stages of the disease.
|
Segmentation |
Details |
|
By Drug Class |
Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Bispecific Antibodies, CAR T-Cell Therapies, Chemotherapeutic Agents, Corticosteroids, Others |
|
By Therapy Type |
Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation, Radiation Therapy, Other Therapies |
|
By Disease Type |
Active Multiple Myeloma, Smoldering Multiple Myeloma (SMM) |
|
By Route of Administration |
Oral, Parenteral (Intravenous/Injectable) |
|
By Distribution Channel |
Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies |
|
By Region |
North America: U.S., Canada, Mexico |
|
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
|
Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
|
South America: Brazil, Argentina, Rest of South America |
Market Segmentation
Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
North America accounted for 45.76% share of the multiple myeloma market in 2023, with a valuation of USD 10.62 billion. This market dominance is primarily attributed to high disease prevalence, advanced healthcare infrastructure, strong presence of key pharmaceutical players, and rapid adoption of novel therapies such as monoclonal antibodies and CAR T-cell treatments. Additionally, investments in oncology research and widespread clinical trial activity have contributed significantly to the region’s leadership in the market.
The market in Asia Pacific is expected to register the fastest growth, with a projected CAGR of 12.28% over the forecast period. This growth is attributed to increasing awareness of multiple myeloma, rising healthcare expenditure, and improving access to modern treatments across developing countries such as China and India.
A growing elderly population, expanding diagnostic capabilities and higher demand for affordable yet effective therapies are also contributing to the market’s rapid expansion in the region. Moreover, domestic pharmaceutical companies are increasingly entering the oncology space, boosting regional innovation and availability.
Regulatory bodies across the region are becoming more receptive to advanced combination therapies for multiple myeloma, enabling faster approval timelines and broader access to innovative treatment options for transplant-ineligible patients.
The multiple myeloma market is characterized by key players employing strategic initiatives to maintain and expand their market positions. Many are diversifying their oncology portfolios by focusing on multi-targeted therapies and combination regimens that enhance treatment efficacy and delay resistance.
Companies are also emphasizing on lifecycle management strategies, including label expansions and reformulations to improve dosing convenience and extend product longevity.
Additionally, collaborations with academic institutions and biotech firms are facilitating early-stage innovation, while investments in real-world evidence generation are helping to support market access and payer negotiations. Market entrants are also leveraging digital health solutions to support treatment monitoring and patient adherence.
Recent Developments (Marketing Approval)
